1. Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer
- Author
-
Ni, Jing, Wang, Mengyun, Wang, Tianpei, Yan, Caiwang, Ren, Chuanli, Li, Gang, Ding, Yanbing, Li, Huizhang, Du, Lingbin, Jiang, Yue, Chen, Jiaping, Wang, Yanong, Xu, Dazhi, Zhu, Meng, Dai, Juncheng, Ma, Hongxia, Hu, Zhibin, Shen, Hongbing, Wei, Qingyi, and Jin, Guangfu
- Abstract
To investigate whether genetic variants may provide additional prognostic value to improve the existing clinical staging system for gastric cancer (GC), we performed two genome-wide association studies (GWASs) of GC survival in the Jiangsu (N= 1049) and Shanghai (N= 1405) cohorts. By using a TCGA dataset, we validated genetic markers identified from a meta-analysis of these two Chinese cohorts to determine GC survival-associated loci. Then, we constructed a weighted polygenic hazard score (PHS) and developed a nomogram in combination with clinical variables. We also evaluated prognostic accuracy with the time-dependent receiver operating characteristic (ROC) curve, net reclassification improvement (NRI) and integrated discrimination improvement (IDI). We identified a single nucleotide polymorphism (SNP) of rs1618332 at 15q15.1 that was associated with the survival of GC patients with a Pvalue of 4.12 × 10−8, and we also found additional 25 SNPs having consistent associations among these two Chinese cohort and TCGA cohort. The PHS derived from these 26 SNPs (PHS-26) was an independent prognostic factor for GC survival (all P< 0.001). The 5-year AUC of PHS-26 was 0.68, 0.66 and 0.67 for Jiangsu, Shanghai and their pooled cohorts, respectively, which increased to 0.80, 0.82 and 0.81, correspondingly, after being integrated into a nomogram together with variables of the clinical model. The PHS-26 could improve the NRIs by 16.20%, 4.90% and 8.70%, respectively, and the IDIs by 11.90%, 8.00% and 9.70%, respectively. The 26-SNP based PHS could substantially improve the accuracy of prognostic assessment and might facilitate precision medicine for GC patients.
- Published
- 2024
- Full Text
- View/download PDF